157 related articles for article (PubMed ID: 10471347)
21. Loss of transforming growth factor-beta (TGF-beta) receptor type I mediates TGF-beta resistance in human papillomavirus type 16-transformed human keratinocytes at late stages of in vitro progression.
Mi Y; Borger DR; Fernandes PR; Pirisi L; Creek KE
Virology; 2000 May; 270(2):408-16. PubMed ID: 10793000
[TBL] [Abstract][Full Text] [Related]
22. Loss of functional transforming growth factor (TGF)-beta type II receptor results in insensitivity to TGF-beta1-mediated apoptosis and Epstein-Barr virus reactivation.
Fukuda M; Kurosaki H; Sairenji T
J Med Virol; 2006 Nov; 78(11):1456-64. PubMed ID: 16998876
[TBL] [Abstract][Full Text] [Related]
23. Effect of Nma on growth inhibition by TGF-betaa in human gastric carcinoma cell lines.
Sasaki T; Sasahira T; Shimura H; Ikeda S; Kuniyasu H
Oncol Rep; 2004 Jun; 11(6):1219-23. PubMed ID: 15138559
[TBL] [Abstract][Full Text] [Related]
24. Mechanisms of mitotic inhibition in corneal endothelium: contact inhibition and TGF-beta2.
Joyce NC; Harris DL; Mello DM
Invest Ophthalmol Vis Sci; 2002 Jul; 43(7):2152-9. PubMed ID: 12091410
[TBL] [Abstract][Full Text] [Related]
25. Gene expression profiling demonstrates that TGF-beta1 signals exclusively through receptor complexes involving Alk5 and identifies targets of TGF-beta signaling.
Karlsson G; Liu Y; Larsson J; Goumans MJ; Lee JS; Thorgeirsson SS; Ringnér M; Karlsson S
Physiol Genomics; 2005 May; 21(3):396-403. PubMed ID: 15769904
[TBL] [Abstract][Full Text] [Related]
26. Characterization of TGF-beta-regulated interleukin-8 expression in human prostate cancer cells.
Lu S; Dong Z
Prostate; 2006 Jun; 66(9):996-1004. PubMed ID: 16541418
[TBL] [Abstract][Full Text] [Related]
27. Growth inhibition due to complementation of transforming growth factor-beta receptor type II-defect by human chromosome 3 transfer in human colorectal carcinoma cells.
Miyafuji Y; Zhong X; Uchida I; Koi M; Hemmi H
J Cell Physiol; 2001 Jun; 187(3):356-64. PubMed ID: 11319759
[TBL] [Abstract][Full Text] [Related]
28. Loss of coordinated androgen regulation in nonmalignant ovarian epithelial cells with BRCA1/2 mutations and ovarian cancer cells.
Evangelou A; Letarte M; Jurisica I; Sultan M; Murphy KJ; Rosen B; Brown TJ
Cancer Res; 2003 May; 63(10):2416-24. PubMed ID: 12750261
[TBL] [Abstract][Full Text] [Related]
29. Sequence-specific enhancer binding protein is responsible for the differential expression of ERT/ESX/ELF-3/ESE-1/jen gene in human gastric cancer cell lines: Implication for the loss of TGF-beta type II receptor expression.
Park SH; Kim YS; Park BK; Hougaard S; Kim SJ
Oncogene; 2001 Mar; 20(10):1235-45. PubMed ID: 11313868
[TBL] [Abstract][Full Text] [Related]
30. The spatiotemporal expression of TGF-beta1 and its receptors during periosteal chondrogenesis in vitro.
Mizuta H; Sanyal A; Fukumoto T; Fitzsimmons JS; Matsui N; Bolander ME; Oursler MJ; O'Driscoll SW
J Orthop Res; 2002 May; 20(3):562-74. PubMed ID: 12038632
[TBL] [Abstract][Full Text] [Related]
31. RNA interference targeting transforming growth factor-beta type II receptor suppresses ocular inflammation and fibrosis.
Nakamura H; Siddiqui SS; Shen X; Malik AB; Pulido JS; Kumar NM; Yue BY
Mol Vis; 2004 Oct; 10():703-11. PubMed ID: 15475878
[TBL] [Abstract][Full Text] [Related]
32. Cell-cycle-dependent expression of transforming growth factor beta type I receptor correlates with differential proliferative effects of TGFbeta1 in articular chondrocytes.
Boumediene K; Félisaz N; Pujol JP
Exp Cell Res; 1998 Aug; 243(1):173-84. PubMed ID: 9716461
[TBL] [Abstract][Full Text] [Related]
33. Restoration of transforming growth factor-beta type II receptor reduces tumorigenicity in the human adrenocortical carcinoma SW-13 cell line.
Yamamoto N; Imai J; Watanabe M; Hiroi N; Sugano S; Yoshino G
Horm Metab Res; 2006 Mar; 38(3):159-66. PubMed ID: 16673206
[TBL] [Abstract][Full Text] [Related]
34. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.
Uhl M; Aulwurm S; Wischhusen J; Weiler M; Ma JY; Almirez R; Mangadu R; Liu YW; Platten M; Herrlinger U; Murphy A; Wong DH; Wick W; Higgins LS; Weller M
Cancer Res; 2004 Nov; 64(21):7954-61. PubMed ID: 15520202
[TBL] [Abstract][Full Text] [Related]
35. Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate cancer in nude mice.
Zhang F; Lee J; Lu S; Pettaway CA; Dong Z
Clin Cancer Res; 2005 Jun; 11(12):4512-20. PubMed ID: 15958637
[TBL] [Abstract][Full Text] [Related]
36. Smad expression in human atherosclerotic lesions: evidence for impaired TGF-beta/Smad signaling in smooth muscle cells of fibrofatty lesions.
Kalinina N; Agrotis A; Antropova Y; Ilyinskaya O; Smirnov V; Tararak E; Bobik A
Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):1391-6. PubMed ID: 15166010
[TBL] [Abstract][Full Text] [Related]
37. Role of PKC and TGF-beta receptor in glucose-induced proliferation of smooth muscle cells.
Yasuda Y; Nakamura J; Hamada Y; Nakayama M; Chaya S; Naruse K; Nakashima E; Kato K; Kamiya H; Hotta N
Biochem Biophys Res Commun; 2001 Feb; 281(1):71-7. PubMed ID: 11178962
[TBL] [Abstract][Full Text] [Related]
38. IGFBP-3 activates TGF-beta receptors and directly inhibits growth in human intestinal smooth muscle cells.
Kuemmerle JF; Murthy KS; Bowers JG
Am J Physiol Gastrointest Liver Physiol; 2004 Oct; 287(4):G795-802. PubMed ID: 15178549
[TBL] [Abstract][Full Text] [Related]
39. Truncation of the TGF-beta type II receptor gene results in insensitivity to TGF-beta in human gastric cancer cells.
Yang HK; Kang SH; Kim YS; Won K; Bang YJ; Kim SJ
Oncogene; 1999 Apr; 18(13):2213-9. PubMed ID: 10327067
[TBL] [Abstract][Full Text] [Related]
40. Differential control of expression of type I and type II receptors of transforming growth factor-beta in colon carcinoma cells.
Periyasamy S; Sun L; Gentry LE; Brattain MG
J Cell Physiol; 1996 Sep; 168(3):711-20. PubMed ID: 8816926
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
